ATBPF:OTC-Antibe Therapeutics Inc (USD)

COMMON STOCK | Medical Devices | OTC

Last Closing Price

USD 0.98

Change

+0.02 (+2.21)%

Market Cap

USD 0.05B

Volume

0.05M

Avg Analyst Target

USD 4.00 (+309.67%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Antibe Therapeutics Inc., a biotechnology company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SNNUF Smith & Nephew plc

+0.51 (+2.78%)

USD16.17B 29.19 15.49
MCRPF MicroPort Scientific Corporati..

+0.32 (+5.34%)

USD12.06B 219.70 53.08
CHEOF Cochlear Limited

N/A

USD11.43B 47.39 29.59
GNNDY GN Store Nord A/S

+1.20 (+0.52%)

USD9.90B 31.32 2.65
GGNDF GN Store Nord A/S

N/A

USD9.64B 30.50 2.65
MEDGF Medacta Group SA

N/A

USD3.28B 36.88 31.69
NHNKY Nihon Kohden Corporation

-0.15 (-0.86%)

USD3.11B 15.25 0.07
NHNKF Nihon Kohden Corporation

N/A

USD2.11B 24.60 -78.50
DWRKF Drägerwerk AG & Co. KGaA

-20.00 (-3.13%)

USD2.06B 37.30 N/A
DGWPF Drägerwerk AG & Co. KGaA

-13.08 (-14.50%)

USD1.68B 5.26 3.10

ETFs Containing ATBPF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -68.50% 11% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.50% 11% F 8% F
Trailing 12 Months  
Capital Gain -61.10% 14% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.10% 14% F 9% F
Trailing 5 Years  
Capital Gain -33.37% 50% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.37% 50% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 45.43% 56% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.43% 56% F 69% D+
Risk Return Profile  
Volatility (Standard Deviation) 90.37% 59% F 35% F
Risk Adjusted Return 50.27% 76% C 75% C
Market Capitalization 0.05B 64% D 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.93 87% B+ 69% D+
Price / Cash Flow Ratio -469.71 97% A+ 98% A+
EV/EBITDA 0.03 97% A+ 86% B
Management Effectiveness  
Return on Equity -51.01% 36% F 17% F
Return on Invested Capital -86.25% 22% F 9% F
Return on Assets -22.94% 55% F 23% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.09 76% C 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector